SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Nexell Therapeutics Inc – ‘8-A12G/A’ on 12/4/02 – EX-99.B

On:  Wednesday, 12/4/02, at 11:00am ET   ·   Accession #:  1017062-2-2054   ·   File #:  0-19153

Previous ‘8-A12G’:  ‘8-A12G/A’ on 7/19/01   ·   Latest ‘8-A12G’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

12/04/02  Nexell Therapeutics Inc           8-A12G/A               2:16K                                    Donnelley R R & S… 11/FA

Amendment to Registration of a Class of Securities   —   Form 8-A
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-A12G/A    Amendment #4 to Form 8-A                            HTML     16K 
 2: EX-99.B     Letter From the Registrant                          HTML      9K 


EX-99.B   —   Letter From the Registrant


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Letter from the Registrant  

Exhibit B

[LOGO OF NEXELL]  

Nexell Therapeutics Inc.
9 Parker

Irvine, California

92618 1605
t.949 470 9011
f.949 770 3291

www.nexellinc.com

December 3, 2002

 

To: The Holders of the Warrants (the “Warrants”) issued Pursuant to a Warrant Agreement dated as of June 17, 1996 between Nexell Therapeutics Inc. (f/k/a VIMRx Pharmaceuticals Inc.) and American Stock Transfer & Trust Company (the “Warrant Agreement”):

     Pursuant to Section 10.1(c)(i) of the Warrant Agreement, as a result of the adjustment to the conversion price of the outstanding Series B Cumulative Convertible Preferred Stock of Nexell Therapeutics Inc. (the “Company”) on October 31, 2002, to $.09 per share, the exercise price for the Warrants, which had been $5.105 per share, has been adjusted to $.2364 per share, and the number of shares of common stock of the Company for which each outstanding Warrant is exercisable has been adjusted from .2938 of a share to 6.34 shares.

     Please also be advised that on October 16, 2002, the Board of Directors of the Company adopted a Plan of Complete Liquidation and Dissolution of the Company (the “Plan”). Please note that it is anticipated that on or about December 23, 2002 there will be a one time cash distribution to common stockholders of record (other than Baxter Healthcare Corporation and its affiliates) as of December 18, 2002 (the “Record Date”) of $.05 per share (the “Distribution”).

     Holders of Warrants will not receive the Distribution unless prior to the Record Date they exercise the Warrants. However, the current exercise price of $.2364 is significantly in excess of the $.05 per share to be distributed in the Distribution.

     It is anticipated that the Company will file a Certificate of Dissolution with the Delaware Secretary of State on or about December 18, 2002 and at or about the same time, close its stock transfer books. Thereafter, no further exercises under the Warrants will be permitted.

  Very truly yours,
  /s/ Victor W. Schmitt
  Victor W. Schmitt
  President, Secretary and Treasurer

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-A12G/A’ Filing    Date    Other Filings
12/23/02
12/18/028-K
Filed on:12/4/02
12/3/02
10/31/02
10/16/028-K
6/17/96
 List all Filings 
Top
Filing Submission 0001017062-02-002054   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 12:13:22.1pm ET